Drug class
Thienopyridine antiplatelet prodrug; irreversible P2Y12 ADP-receptor antagonist
Mechanism of action
Requires hepatic bioactivation to an active thiol metabolite that irreversibly binds platelet P2Y12 receptors, inhibiting ADP-mediated activation of the glycoprotein IIb/IIIa complex and platelet aggregation.
General use cases
- Prevention of atherothrombotic events in patients with recent myocardial infarction, recent ischaemic stroke or established peripheral arterial disease
- Acute coronary syndrome, including non-ST-elevation and ST-elevation myocardial infarction, in combination with aspirin under the applicable label
- Prevention of stent thrombosis after percutaneous coronary intervention as part of dual antiplatelet therapy; duration is patient- and product-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
